Belite Bio (BLTE) Stock: Buy, Sell, or Hold?
BLTE - Belite Bio, Inc American Depositary Shares
$173.79
-1.28 (-0.73%)
âŧ
5d:
+1.58%
30d:
-2.88%
90d:
+26.99%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When BLTE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BLTE is fairly priced but lacks strong directional signals. At -22.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BLTE is fairly priced but lacks strong directional signals. At -22.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$79.17
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$49.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BLTE is currently trading at $173.79, which is considered slightly high relative to its 30-day fair value range of $156.04 to $177.37. From a valuation perspective, the stock is trading at a discount (Forward PE: 76.9) compared to its historical average (165.0). Remarkably, the market is currently pricing in an annual earnings decline of 22.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BLTE is in a uptrend. Immediate support is located at $150.16, while resistance sits at $198.58.
Market Sentiment: BLTE scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $228.89 (+31.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BLTE is in a uptrend. Immediate support is located at $150.16, while resistance sits at $198.58.
Market Sentiment: BLTE scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $228.89 (+31.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$156.04 -
$177.37
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.9%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.7% below Wall St target ($228.89)
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$156.04 -
$177.37
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$150.16
Resistance Level
$198.58
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
76.90
Wall Street Target
$228.89
(+31.7%)
Valuation Discount vs History
-22.5% cheaper
PE vs Historical
76.9 vs 165.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.5%
(market-implied from PE analysis)
1-Year Target
$156.41
(-10%)
2-Year Target
$140.77
(-19%)
3-Year Target
$126.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 77â165)
$271.84
(+56%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 76.9 to 165.0
Stabilization Target:
$372.90
(+114.6%)
PE Expansion Potential:
+114.6%
Share & Embed Analysis
Last updated: September 13, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLTE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Nathan L Mata
SELL
1000 shares
2026-04-22
Nathan L Mata
SELL
1000 shares
2026-04-20
Nathan L Mata
SELL
1000 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
